Type 2 Diabetes Mellitus (T2DM) and Insulin Resistance (IR) are two pandemic metabolic diseases that are reportedly increasing worldwide. Therefore, there is an urgent demand to develop new regenerative-medicine approaches based on the use of in-vitro self-derived spare tissues. We apply the reprogramming technology to selected cohort of patients’ fibroblasts with high reported risk of developing IR and T2DM and healthy controls. We then use this cellular platform to obtain in-vitro glucose sensitive cell types to potentially unravel basic transcriptional and epigenetic mechanisms underlying the onset and progression of T2DM.